HC Wainwright & Co. Maintains Buy on Savara, Lowers Price Target to $9
HC Wainwright & Co. analyst Matthew Caufield maintains Savara (NASDAQ:SVRA) with a Buy and lowers the price target from $10 to $9.
Follow the latest Savara Inc. (SVRA) news and market headlines alongside the live SVRA price. Stay informed on what's moving SVRA.
HC Wainwright & Co. analyst Matthew Caufield maintains Savara (NASDAQ:SVRA) with a Buy and lowers the price target from $10 to $9.
U.S. stocks fell Friday: Dow -0.5%, S&P 500 -2.0%, Nasdaq -3.4%. Tech led losses; consumer staples rose. Gold, silver and global markets also declined.
Savara (NASDAQ: SVRA) shares fell Friday after the FDA said it will miss its November 22, 2026 PDUFA target date for molgramostim.
Savara Inc. (NASDAQ:SVRA), a clinical-stage biopharmaceutical company focused on rare respiratory diseases, today announced that the U.S. Food and Drug Administration (FDA) has communicated that it will not meet the
XBI and IBB lagged SPY and QQQ as two FDA decisions and fresh Alzheimer's and obesity-drug data put biotech ETFs in focus.
HC Wainwright & Co. analyst Matthew Caufield assumes Savara (NASDAQ:SVRA) with a Buy rating and announces Price Target of $10.
News and data on this page is provided by our partnered third-party news and market data provider, with the original publisher credited on each article. All third-party content reflects the views of the original publisher and does not represent the views of MEXC. Price and market data shown on this page are provided by third-party data providers and may be delayed. MEXC offers trading products related to SVRA, including RealStocks and Stock Futures.
The content on this page is provided for informational purposes only and does not constitute investment, financial, or trading advice. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of any news or market data shown. Trading U.S. stocks and related products involves significant risk, and prices can move sharply in a short period. Past performance does not guarantee future results. Please conduct your own research and assess your financial situation and risk tolerance before making any investment decisions. MEXC is not liable for any losses arising from the use of this information.